Pfizer Inc Stock Research

Market Summary

USD40.27-0.12

Delayedas of 27 Mar 2023, 11:24 am

-0.30%

PFE Alerts

1 major insider sales recently.
Big jump in Earnings (Y/Y)

PFE Stock Price

PFE RSI Chart

PFE Valuation

Market Cap

226.5B

Price/Earnings (Trailing)

7.22

Price/Sales (Trailing)

2.26

EV/EBITDA

6.25

Price/Free Cashflow

8.7

PFE Price/Sales (Trailing)

PFE Profitability

EBT Margin

34.61%

Return on Equity

32.79%

Return on Assets

15.92%

Free Cashflow Yield

11.49%

PFE Fundamentals

PFE Revenue

Revenue (TTM)

100.3B

Revenue Y/Y

1.9%

Revenue Q/Q

7.3%

PFE Earnings

Earnings (TTM)

31.4B

Earnings Y/Y

47.19%

Earnings Q/Q

-41.98%

Price Action

52 Week Range

39.2354.96

(Low)(High)

Last 7 days

0.1%

Last 30 days

-4.7%

Last 90 days

-22.1%

Trailing 12 Months

-21.3%

PFE Financial Health

Current Ratio

1.22

PFE Investor Care

Dividend Yield

3.99%

Dividend/Share (TTM)

1.61

Buy Backs (1Y)

0.04%

Diluted EPS (TTM)

5.47

Peers (Alternatives to Pfizer)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	401.1B	94.9B	-3.25%	-11.17%	22.36	4.23	1.25%	-14.07%
LLY	302.8B	28.5B	2.15%	17.94%	48.48	10.61	0.79%	11.88%
MRK	272.8B	59.3B	-3.99%	33.34%	17.88	4.63	21.72%	11.27%
PFE	226.5B	100.3B	-4.70%	-21.30%	7.22	2.26	23.43%	42.74%
BMY	143.9B	46.2B	-5.09%	-4.47%	22.74	3.12	-0.49%	-9.54%
MID-CAP
PRGO	4.6B	4.5B	-7.51%	-10.48%	-32.41	1.02	7.56%	-104.06%
RETA	3.1B	2.2M	88.62%	133.17%	-10.04	1.4K	-80.71%	-4.88%
SMALL-CAP
SUPN	1.9B	667.2M	-7.26%	10.85%	31.38	2.86	15.09%	13.64%
TLRY	1.6B	602.5M	-7.75%	-62.41%	-2.78	2.67	18.18%	-18.59%
CGC	923.6M	478.9M	-20.50%	-75.95%	-0.29	1.93	-31.50%	-634.70%
INVA	785.3M	285.2M	-7.87%	-42.24%	3.57	2.75	-27.21%	-40.28%
CRON	738.3M	114.5M	-10.60%	-51.38%	-4.38	6.45	27.90%	57.40%
ACRS	534.2M	29.8M	-36.88%	-54.59%	-6.15	17.95	340.05%	4.35%
OCUL	379.8M	51.5M	-18.81%	-6.64%	-5.35	7.38	18.32%	-984.05%
ENDP	94.1M	2.3B	-43.99%	-88.43%	-0.03	0.04	-22.53%	-376.66%

Financials for Pfizer

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	0.5%	100,330	99,879	101,276	92,433	81,288
S&GA Expenses	4.1%	13,677	13,136	12,644	12,519	12,703
EBITDA	4.2%	36,171	34,708	33,956	34,344	-
EBITDA Margin	3.7%	0.36*	0.35*	0.34*	0.37*	-
Earnings Before Taxes	4.2%	34,729	33,325	32,167	27,669	24,311
EBT Margin	3.7%	0.35*	0.33*	0.32*	0.30*	-
Interest Expenses	4.3%	1,442	1,383	1,440	1,475	1,467
Net Income	5.4%	31,372	29,771	29,309	24,966	21,979
Net Income Margin	4.9%	0.31*	0.30*	0.29*	0.27*	-
Free Cahsflow	11.4%	26,031	23,362	28,443	31,783	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	1.0%	197,000	195,000	195,290	183,841	181,000
Current Assets	-27.2%	51,259	70,403	67,466	54,420	59,693
Cash Equivalents	-68.0%	416	1,298	1,780	2,470	1,944
Inventory	-5.6%	8,981	9,513	10,454	9,979	9,059
Net PPE	5.4%	16,274	15,441	15,244	15,109	14,882
Goodwill	6346.0%	51,375	797	49,891	50,211	49,208
Liabilities	-1.1%	101,288	102,459	107,821	101,155	104,013
Current Liabilities	-4.9%	42,138	44,314	47,410	39,268	42,671
LT Debt, Current	-0.2%	2,560	2,566	1,276	260	1,636
LT Debt, Non Current	0.8%	32,884	32,629	34,294	35,656	36,000
Shareholder's Equity	3.3%	95,661	92,631	87,469	82,685	77,201
Retained Earnings	2.2%	125,656	122,967	116,608	111,193	103,394
Additional Paid-In Capital	0.5%	91,802	91,359	91,183	90,844	90,591
Accumulated Depreciation	-0.3%	14,931	14,969	15,358	15,074	-
Shares Outstanding	0.3%	5,607	5,593	5,617	-	-
Minority Interest	-1.2%	256	259	261	261	262

* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	10.0%	29,267	26,599	31,454	34,583	32,580
Share Based Compensation	-13.1%	872	1,004	1,162	1,096	1,182
Cashflow From Investing	-13.1%	-15,783	-13,959	-23,408	-20,232	-22,546
Cashflow From Financing	-12.6%	-14,834	-13,170	-8,510	-13,587	-9,816
Buy Backs	0%	2,000	2,000	2,000	2,000	0.00

Risks for PFE

What is the probability of a big loss on PFE?

46.1%

Probability that Pfizer stock will be more than 20% underwater in next one year

6.5%

Probability that Pfizer stock will be more than 30% underwater in next one year.

Probability that Pfizer stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PFE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Pfizer was unfortunately bought at previous high price.

Drawdowns

Returns for PFE

Cumulative Returns on PFE

7.2%

10-Year Cumulative Returns

8.1%

7-Year Cumulative Returns

6.8%

5-Year Cumulative Returns

14.6%

3-Year Cumulative Returns

What are the long-term rolling returns for PFE?

FIve years rolling returns for Pfizer.

Annualized Returns

Which funds bought or sold PFE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-15	B. Riley Wealth Advisors, Inc.	added	2.73	2,991,590	17,741,600	0.50%
2023-03-13	Claro Advisors LLC	added	7.02	130,979	2,972,980	0.97%
2023-03-10	BAILLIE GIFFORD & CO	unchanged	-	3,878	23,878	-%
2023-03-10	Financial Alternatives, Inc	new	-	383,941	383,941	0.38%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	reduced	-10.00	11,741,400	229,834,000	0.25%
2023-03-10	MATHER GROUP, LLC.	added	5.48	507,782	2,670,780	0.05%
2023-03-08	SHEETS SMITH WEALTH MANAGEMENT	reduced	-0.01	393,224	2,696,220	0.42%
2023-03-08	Capital Asset Advisory Services LLC	added	11.08	665,852	2,723,850	0.22%
2023-03-07	Nordwand Advisors, LLC	new	-	5,119,080	5,119,080	0.64%
2023-03-06	BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL	reduced	-0.68	1,043,020	7,441,020	2.83%

Latest Funds Activity

Are funds buying PFE calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own PFE

No. of Funds

Pfizer News

Schedule 13G FIlings of Pfizer

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	8.94%	501,636,220	SC 13G/A
Feb 07, 2023	state street corp	5.08%	284,943,697	SC 13G/A
Feb 03, 2023	blackrock inc.	7.9%	442,868,761	SC 13G/A
Feb 14, 2022	state street corp	5.09%	285,771,591	SC 13G/A
Feb 10, 2022	vanguard group inc	8.29%	465,274,925	SC 13G/A
Feb 01, 2022	blackrock inc.	7.3%	409,985,645	SC 13G/A
Feb 12, 2021	state street corp	5.03%	279,831,373	SC 13G
Feb 10, 2021	vanguard group inc	8.06%	447,958,747	SC 13G/A
Jan 29, 2021	blackrock inc.	7.1%	396,973,512	SC 13G/A
Feb 13, 2020	state street corp	5.28%	292,628,794	SC 13G

PFE Fair Value

Pfizer fair value in different scenarios

The table shows the Fair Value estimates for Pfizer for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	- -	- -	- -	- -	- -
Current Inflation	51.05 26.77%	62.08 54.16%	122.82 204.99%	161.21 300.32%	292.19 625.58%
Very High Inflation	- -	- -	- -	- -	- -

Historical Pfizer Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Pfizer

View All Filings

Date Filed	Form Type	Document
Mar 23, 2023	4/A	Insider Trading
Mar 23, 2023	SC 13G/A	Major Ownership Report
Mar 22, 2023	PX14A6G	PX14A6G
Mar 21, 2023	4	Insider Trading
Mar 21, 2023	4	Insider Trading
Mar 17, 2023	4	Insider Trading
Mar 17, 2023	ARS	ARS
Mar 17, 2023	4	Insider Trading
Mar 17, 2023	4	Insider Trading
Mar 16, 2023	DEF 14A	DEF 14A

Latest Insider Trading transactions for PFE

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-15	DAMICO JENNIFER B.	sold	-396,678	40.02	-9,912	svp & controller
2023-02-27	SAHNI PAYAL	sold (taxes)	-52,891	40.78	-1,297	executive vice president
2023-02-27	DAMICO JENNIFER B.	sold (taxes)	-58,193	40.78	-1,427	svp & controller
2023-02-27	McDermott Michael	sold (taxes)	-125,643	40.78	-3,081	executive vice president
2023-02-25	SAHNI PAYAL	acquired	204,202	22.89	8,921	executive vice president
2023-02-25	DAMICO JENNIFER B.	acquired	255,224	22.89	11,150	svp & controller
2023-02-25	SUSMAN SALLY	acquired	1,670,600	22.89	72,984	executive vice president
2023-02-25	BOURLA ALBERT	sold (taxes)	-1,812,740	41.75	-43,419	chairman & ceo
2023-02-25	McDermott Michael	sold (taxes)	-392,417	42.9153	-9,144	executive vice president
2023-02-25	LANKLER DOUGLAS M	sold (taxes)	-1,101,740	41.75	-26,389	executive vice president

About Pfizer

Albert Bourla

www.pfizer.com

65535

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PFE Income Statement

2022-12-31

Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Income Statement [Abstract]

Revenues

$ 100,330

$ 81,288

$ 41,651

Costs and expenses:

Cost of sales

^[1]

34,344

30,821

8,484

Selling, informational and administrative expenses

^[1]

13,677

12,703

11,597

Research and development expenses

^[1]

11,428

10,360

8,709

Acquired in-process research and development expenses

^[2]

953

3,469

684

Amortization of intangible assets

3,609

3,700

3,348

Restructuring charges and certain acquisition-related costs

1,375

802

579

Other (income)/deductions––net

217

(4,878)

1,213

Income from continuing operations before provision/(benefit) for taxes on income

^[3],[4],[5]

34,729

24,311

7,036

Provision/(benefit) for taxes on income

3,328

1,852

370

Income from continuing operations

31,401

22,459

6,666

Discontinued operations––net of tax

(434)

2,529

Net income before allocation to noncontrolling interests

31,407

22,025

9,195

Less: Net income attributable to noncontrolling interests

Net income attributable to Pfizer Inc. common shareholders

$ 31,372

$ 21,979

$ 9,159

Earnings per common share––basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)

$ 5.59

$ 4.00

$ 1.19

Discontinued operations––net of tax (in dollars per share)

(0.08)

0.46

Net income attributable to Pfizer Inc. common shareholders (in dollars per share)

5.59

3.92

1.65

Earnings per common share––diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)

5.47

3.93

1.18

Discontinued operations––net of tax (in dollars per share)

(0.08)

0.45

Net income attributable to Pfizer Inc. common shareholders (in dollars per share)

$ 5.47

$ 3.85

$ 1.63

Weighted-average shares––basic

5,608

5,601

5,555

Weighted-average shares––diluted

5,733

5,708

5,632

[1]	Exclusive of amortization of intangible assets.
[2]	See Note 1L.
[3]	Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $314 million in 2022, $166 million in 2021 and $278 million in 2020. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $231 million of costs in 2021 and $222 million of costs in 2020 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation. Amortization of intangible assets is not allocated to our operating segments for all periods presented.
[4]	2021 v. 2020––The domestic income in 2021 versus domestic loss in 2020 was mainly related to Comirnaty income, lower asset impairment charges, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and higher net gains from equity securities, partially offset by higher R&D expenses. The increase in the international income was primarily related to Comirnaty income, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and lower asset impairment charges.
[5]	2022 v. 2021––The decrease in domestic income is primarily related to net losses on equity securities in 2022 versus net gains on equity securities in 2021, lower net periodic benefit credits and higher restructuring charges and certain acquisition-related costs, partially offset by Paxlovid income and lower acquired IPR&D expenses. The increase in the international income is primarily related to Paxlovid and Comirnaty income partially offset by lower net periodic benefit credits.

PFE Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($)
$ in Millions

Dec. 31, 2022

Dec. 31, 2021

Assets

Cash and cash equivalents

$ 416

$ 1,944

Short-term investments

22,316

29,125

Trade accounts receivable, less allowance for doubtful accounts: 2022—$449; 2021—$492

10,952

11,479

Inventories

^[1]

8,981

9,059

Current tax assets

3,577

4,266

Other current assets

5,017

3,820

Total current assets

51,259

59,693

Equity-method investments

11,033

16,472

Long-term investments

4,036

5,054

Property, plant and equipment

16,274

14,882

Identifiable intangible assets

^[2]

43,370

25,146

Goodwill

^[3]

51,375

49,208

Noncurrent deferred tax assets and other noncurrent tax assets

6,693

3,341

Other noncurrent assets

13,163

7,679

Total assets

197,205

181,476

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2022—$2,560; 2021—$1,636

2,945

2,241

Trade accounts payable

6,809

5,578

Dividends payable

2,303

2,249

Income taxes payable

1,587

1,266

Accrued compensation and related items

3,407

3,332

Deferred revenues

2,520

3,067

Other current liabilities

22,568

24,939

Total current liabilities

42,138

42,671

Long-term debt

32,884

36,195

Pension and postretirement benefit obligations

2,250

3,724

Noncurrent deferred tax liabilities

1,023

349

Other taxes payable

9,812

11,331

Other noncurrent liabilities

13,180

9,743

Total liabilities

101,288

104,013

Commitments and Contingencies

Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2022 and December 31, 2021

Common stock, $0.05 par value; 12,000 shares authorized; issued: 2022—9,519; 2021—9,471

476

473

Additional paid-in capital

91,802

90,591

Treasury stock, shares at cost: 2022—3,903; 2021—3,851

(113,969)

(111,361)

Retained earnings

125,656

103,394

Accumulated other comprehensive loss

(8,304)

(5,897)

Total Pfizer Inc. shareholders’ equity

95,661

77,201

Equity attributable to noncontrolling interests

256

262

Total equity

95,916

77,462

Total liabilities and equity

$ 197,205

$ 181,476

[1]	The decrease from December 31, 2021 reflects lower levels of Comirnaty, partially offset by new products acquired through recent acquisitions and higher Paxlovid inventory levels.
[2]	The increase is primarily due to acquisitions (see Note 2A), partially offset by amortization expense.
[3]	As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see Note 1A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed this re-allocation during the fourth quarter 2022 and concluded that none of our goodwill was impaired. Our goodwill balance continues to be assigned within the Biopharma reportable segment.